U.S. markets closed
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • Dow 30

    34,798.00
    +33.20 (+0.10%)
     
  • Nasdaq

    15,047.70
    -4.50 (-0.03%)
     
  • Russell 2000

    2,248.07
    -10.97 (-0.49%)
     
  • Crude Oil

    73.95
    +0.65 (+0.89%)
     
  • Gold

    1,750.60
    +0.80 (+0.05%)
     
  • Silver

    22.42
    -0.26 (-1.16%)
     
  • EUR/USD

    1.1718
    -0.0029 (-0.25%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • GBP/USD

    1.3661
    -0.0059 (-0.43%)
     
  • USD/JPY

    110.6630
    +0.3620 (+0.33%)
     
  • BTC-USD

    43,381.32
    +609.99 (+1.43%)
     
  • CMC Crypto 200

    1,067.20
    -35.86 (-3.25%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19.

  • Roche Holding AG (OTC: RHHBY) and Atea jointly develop AT-527, an oral direct-acting antiviral agent derived from Atea's purine nucleotide prodrug platform.

  • On Day 2, patients receiving AT-527 experienced a 0.7 log10 (80%) greater mean reduction from baseline viral load than placebo.

  • AT-527's antiviral activity was also observed in patients with higher baseline viral loads.

  • The AT-527 arm achieved SARS-CoV-2 clearance as early as Day 2 (in 6% of patients), Day 8 (in 7% of patients), Day 10 (in 33% of patients), and Day 12 (in 31% of patients) compared to 0% of patients in the placebo arm.

  • By Day 14 (last viral sampling study day), approximately 47% of patients in the AT-527 arm and 22% in the placebo arm had no detectable RNA virus.

  • No drug-related serious adverse events were reported, and AT-527 was safe and well-tolerated.

  • Final data from the complete Phase 2 program will be submitted to an upcoming medical congress or a peer-reviewed publication.

  • Price Action: AVIR shares are down 7.87% at $22.49 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.